Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company's products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism. The Company's products are under various clinical trials, including Chronocort, which is in Phase III clinical trial; Infacort, which is in Phase III clinical trial, and Native Oral Testosterone, which is in Phase I clinical trial.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: LON:DNL
- CUSIP: N/A
- Web: www.diurnal.co.uk/
Capitalization:- Market Cap: £69.85 million
- Outstanding Shares: 52,320,000
Average Prices:- 50 Day Moving Avg: GBX 132.54
- 200 Day Moving Avg: GBX 130.46
- 52 Week Range: GBX 105 - GBX 142.50
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: GBX 0.33 per share
- Price / Book: 4.05
Profitability:- EBIDTA: ($12,060,000.00)
- Return on Equity: -39.52%
- Return on Assets: -29.56%
Misc:- Average Volume: 1,243 shs.
Frequently Asked Questions for Diurnal Group PLC (LON:DNL)
What is Diurnal Group PLC's stock symbol?
Diurnal Group PLC trades on the London Stock Exchange (LON) under the ticker symbol "DNL."
When will Diurnal Group PLC make its next earnings announcement?
Where is Diurnal Group PLC's stock going? Where will Diurnal Group PLC's stock price be in 2017?
2 brokerages have issued 12 month price objectives for Diurnal Group PLC's shares. Their forecasts range from GBX 169 to GBX 178. On average, they expect Diurnal Group PLC's stock price to reach GBX 173.50 in the next twelve months. View Analyst Ratings for Diurnal Group PLC.
Who are some of Diurnal Group PLC's key competitors?
Some companies that are related to Diurnal Group PLC include Aralez Pharmaceuticals (ARLZ), Female Health Company (The) (VERU), BioLife Solutions (BLFS), Concordia International Corp. (CXRX), SCYNEXIS (SCYX), Evoke Pharma (EVOK), Juniper Pharmaceuticals (JNP), Amryt Pharma PLC (AMYT), Histogenics Corporation (HSGX), Pernix Therapeutics Holdings (PTX), Intellipharmaceutics International (IPCI), Cellectar Biosciences (CLRB), Apricus Biosciences (APRI), Eyegate Pharmaceuticals (EYEG), Venture Life Group PLC (VLG), Neuralstem (CUR), Immune Pharmaceuticals (IMNP) and Galena Biopharma (GALE).
Who are Diurnal Group PLC's key executives?
Diurnal Group PLC's management team includes the folowing people:
- Martin Whitaker Ph.D., Chief Executive Officer, Executive Director
- Richard Edward Bungay, Chief Financial Officer
- Richard Ross, Chief Scientific Officer, Director
- David Eckland, Medical Director
- Hiep Huatan Ph.D., Chief Development Offer
- Daniel Nelson Margetson, CMC Director
- John Porter, Medical Affairs Director
- Michael Withe, Commercial Director
- Peter Vance Allen, Non-Executive Chairman of the Board
- Alan Michael Raymond Ph.D., Non-Executive Director
How do I buy Diurnal Group PLC stock?
Shares of Diurnal Group PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Diurnal Group PLC's stock price today?
One share of Diurnal Group PLC stock can currently be purchased for approximately GBX 133.50.
MarketBeat Community Rating for Diurnal Group PLC (LON DNL)MarketBeat's community ratings are surveys of what our community members think about Diurnal Group PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Diurnal Group PLC (LON:DNL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | GBX 173.50 |
Analysts' Ratings History for Diurnal Group PLC (LON:DNL)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 9/6/2017 | Numis Securities Ltd | Reiterated Rating | Buy | GBX 169 |  |
| 6/15/2017 | Panmure Gordon | Reiterated Rating | Buy | GBX 178 | |
(Data available from 9/25/2015 forward)
Earnings History for Diurnal Group PLC (LON:DNL)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Diurnal Group PLC (LON:DNL)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Diurnal Group PLC (LON:DNL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Diurnal Group PLC (LON:DNL)Insider Trades by Quarter for Diurnal Group PLC (LON:DNL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/7/2017 | John Goddard | Insider | Buy | 10,791 | GBX 5 | £539.55 | |
| 1/16/2017 | Alan Raymond | Insider | Buy | 9,000 | GBX 110 | £9,900 | |
| 1/13/2017 | Sam Williams | Insider | Buy | 9,248 | GBX 108 | £9,987.84 | |
(Data available from 1/1/2013 forward)
Headline Trends for Diurnal Group PLC (LON:DNL)
Latest Headlines for Diurnal Group PLC (LON:DNL)
| Source: |
|
Diurnal Group PLC (DNL) Chart for Monday, September, 25, 2017
